Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.00
Bid: 54.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.704%)
Open: 55.00
High: 55.00
Low: 55.00
Prev. Close: 55.00
BSC Live PriceLast checked at -
British Smaller Companies VCT 2 is an Investment Trust

To create a portfolio that blends a mix of businesses operating in established industries with those that offer opportunities in the application and development of innovation.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

13 Nov 2012 14:27

RNS Number : 0229R
British Smaller Companies VCT2 Plc
13 November 2012
 



 

British Smaller Companies VCT2 plc ("the Company")

 

Interim Management Statement

For the quarter ended 30 September 2012

 

British Smaller Companies VCT2 plc presents its interim management statement for the period from 1 July to the date of this announcement, including the results for the quarter to 30 September 2012. This constitutes the Company's second interim management statement for the financial year ending 31 December 2012, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmep.com.

 

The total return at 30 September 2012, calculated by reference to the net asset value per Ordinary share and the cumulative dividends paid per Ordinary share, is 100.0 pence per Ordinary share. In the quarter there has been no movement in the total return to Shareholders.

 

The unaudited net asset value per Ordinary share as at 30 September 2012 was 68.0p (30 June 2012: 68.0p). Not included within this value is the interim dividend of 2.0 pence per Ordinary share and a Special Dividend of 0.5 per Ordinary share which were paid on 26 October 2012.

 

The number of Ordinary shares in issue at 30 September 2012 was 38,243,718 (30 June 2012: 38,243,718). In addition, at 30 September 2012, the Company held 1,178,356 Ordinary shares in Treasury (30 June 2012: 1,178,356).

 

 

Net assets at 30 September 2012 comprised the following:

£000

% of net assets

Unquoted investments at fair value

9,421

36.2

Quoted investments at bid price

2,124

8.2

Gilt investments

919

3.5

Total investments

12,464

47.9

Cash and cash equivalents

12,955

49.8

Other net current assets

583

2.3

Net assets

26,002

100.0

 

The ten largest investments by valuation at 30 September 2012 were as follows:

 

£000

% of net assets

Seven Technologies Limited

1,262

4.8

Displayplan Holdings Limited

1,244

4.8

Deep-Secure Ltd

1,055

4.1

Immunobiology Limited

987

3.8

Digital Healthcare Limited

921

3.6

Bluebell Telecom Group Limited

545

2.1

Power Oasis Limited

500

2.0

Iomart Group plc

416

1.6

Bagel Nash Limited

400

1.5

Harvey Jones Limited

400

1.5

Top ten investments

7,730

29.8

Other investments

3,815

14.6

Gilt investments

919

3.5

Total investments

12,464

47.9

 

 

During the three months ended 30 September 2012 the Company made a total of 4 investments, two into new portfolio companies and two follow-on investments into existing portfolio companies.

 

In August the Company invested £0.78 million into Insider Technologies Limited, an established provider of monitoring and scheduling software to the financial services and national security sectors, as well as £0.125 million into Hargreaves Services plc, Britain's largest bulk haulage company.

 

In addition, during the period, the Company made two additional follow-on investments into existing portfolio companies. In July the Company invested £0.16 million into Vianet Group plc (formerly Brulines Group plc.) a leading provider of monitoring dispense protection systems for draught alcoholic drinks in the UK licensed on-trade. Whilst in August the Company invested £0.9 million into Immunobiology Limited, a company involved in the development of high efficacy vaccines for infectious diseases including influenza, tuberculosis, meningitis and hepatitis.

 

In the 3 months to September 2012 cash proceeds of £3.74 million have been received relating to the sale of the Company's holdings in Primal Pictures Limited and Sirigen Group Limited as well as from its part disposal of shares held in May Gurney Integrated Services plc, in total representing a profit of £1.82 million on original cost.

 

Following the end of the period the Company has made part disposals of two AIM listed investments, Brady Plc and Iomart Plc. This raised cash proceeds of £190,000 compared to a carrying value at 30 September 2012 of 178,000 giving rise to a return on cost of 2.02 times.

 

Performance

Valuations have remained stable this quarter. The total return, calculated by reference to the net asset value plus cumulative dividends, has remained constant at 100.0 pence per Ordinary share, with cumulative dividends now representing 32.0 pence per Ordinary share. The Company has also paid an interim and special dividend totalling 2.5 pence per Ordinary share on 26 October 2012.

 

Outlook

The Board believes that the current economic climate will continue to create investment opportunities in the short to medium term in well run and managed UK businesses that need capital to expand but are facing a shortage of finance. History has shown us that cautious investments made in the low point of the economic cycle have resulted in the highest portfolio returns. Additionally the investment limit applying to venture capital trusts has been increased to £5 million per investment in any one year. To take full advantage of this market opportunity the Board is seeking to increase the investment capacity of the Company over the coming months via a joint fund raising offer with British Smaller Companies VCT to raise in aggregate up to £15 million in gross proceeds.

 

 

13 November 2012

 

For further information please contact:

 

David Hall YFM Private Equity Limited Tel: 0113 294 5039

Matt Thomas N+1 Singer Tel: 0203 205 7500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZMMMMDFFGZZM
Date   Source Headline
28th Jun 20249:43 amRNSPayment of dividend and issue of shares
25th Jun 20247:00 amRNSTransaction in Own Shares
14th Jun 202412:30 pmRNSInterim Management Statement
13th Jun 202410:03 amRNSResult of AGM
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.